Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Set & Setting

DMT for Set & Setting

9 papers and 3 clinical trials exploring dmt as a treatment for set & setting.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 264 million individuals worldwide suffer from depression, with many seeking innovative treatment options such as psychedelic-assisted therapy.

Set & Setting

The concept of 'set and setting' is critical in psychedelic research, influencing therapeutic outcomes in clinical environments. Creating optimal conditions is essential for maximising the efficacy and safety of psychedelic-assisted therapies, particularly in the context of mental health disorders.

Full Set & Setting profile

Academic Research

9 papers
Open Accessindividual

Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects

In a randomised, double‑blind, placebo‑controlled within‑subjects trial in 31 healthy volunteers, an ayahuasca‑inspired N,N‑DMT plus harmine formulation produced acute increases in mindfulness and both self‑ and other‑directed compassion one day after dosing compared with harmine or placebo, with larger effects in high‑sensitivity individuals. These findings suggest the formulation may have therapeutic potential similar to traditional ayahuasca and warrant further clinical investigation.

Published
June 19, 2025
Journal
Journal of Psychopharmacology
Authors
Aicher, H. D., Wicki, I. A., Meling, D., Mueller, M. J., Dornbierer, D. A., Scheidegger, M.
Open Accessindividual

Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants

In a double‑blind, placebo‑controlled crossover study in 22 healthy adults, continuous DMT infusions showed dose‑proportional pharmacokinetics and rapidly produced dose‑dependent subjective effects that plateaued after 30 minutes with a ceiling for positive effects at 1.8 mg/min, whereas 2.4 mg/min increased anxious ego dissolution and anxiety and produced moderate acute tolerance. A self‑guided titration enabled participants to achieve effects comparable to the 1.8 mg/min dose, supporting dose‑finding and adjustable dosing strategies for future DMT research.

Published
December 19, 2024
Journal
Neuropsychopharmacology
Authors
Erne, L., Vogt, S. B., Müller, L., Nuraj, A., Becker, A., Klaiber, A., Zuparic, M., Varghese, N., Eckert, A., Rudin, D., Luethi, D., Liechti, M. E.
Open Accessindividual

Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors

In a sample of 863 regular meditators who had used psychedelics, 73.5% reported that psychedelic use positively influenced the quality of their meditation. Machine‑learning analyses (elastic net, random forest) identified greater frequency of psychedelic use, intentional set‑up for trips, higher agreeableness and reported N,N‑DMT exposure as the strongest predictors of perceiving such benefits, though causal claims require longitudinal or randomised studies.

Published
August 28, 2024
Journal
MedRvix
Authors
Jiwani, Z., Goldberg, S. B., Stroud, J., Young, J., Curtin, J., Dunne, J. D., Simonsson, O., Webb, C. A., Carhart-Harris, R., Schlosser, M.
Open Accessindividual

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

This Phase 2a open‑label, dose‑escalation study in six patients with treatment‑resistant depression found that a single‑day session of vapourised N,N‑dimethyltryptamine produced rapid and sustained reductions in depressive symptoms (mean MADRS change −22 at Day 7 and −17 at one month), with 83.3% response and 66.7% remission at Day 7 and 66.7% response and 50% remission at one month. The authors highlight the non‑invasive, short‑acting delivery as a practical advantage that could improve accessibility of psychedelic-assisted interventional psychiatry.

Published
January 4, 2024
Journal
MedRvix
Authors
Falchi-Carvalho, M., Barros, H., Bolcont, R., Laborde, S., Wießner, I., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., Almeida, R., Macedo, R. K. A., Arichelle, F., Pantrigo, E. J., Arcoverde, E., Galvão-Coelho, N. L., Araújo, D. B., Palhano-Fontes, F.
Paywallindividual

The Power of Social Attribution: Perspectives on the Healing Efficacy of Ayahuasca

The paper argues that Indigenous and biomedical frameworks for ayahuasca are ontologically incommensurate: Indigenous efficacy is understood as correct communication with non‑human powers mediated by ritual, whereas modern medicine explains effects via MAO inhibition and dimethyltryptamine‑triggered neuropsychological processes, so one cannot legitimately be used to validate the other. It also highlights the colonial dynamics in neo‑shamanic and recreational appropriation and calls for these issues to be questioned and resolved in any application of ayahuasca.

Published
October 28, 2021
Journal
Frontiers in Psychology
Authors
Brabec de Mori, B.
Open Accessindividual

An Encounter with the Other: A Thematic Analysis of Accounts of DMT Experiences from a Naturalistic Field Study

In the first naturalistic field study using immediate micro-phenomenological interviews, thematic analysis of 36 breakthrough DMT experiences found near-universal encounters with other “beings” (94%) and immersive other “worlds” (100%), characterised by consistent themes of role, appearance, demeanour, communication and interaction. The authors relate these entity encounters to alien-abduction, shamanic and near-death phenomena and discuss possible neural mechanisms and implications for psychotherapy.

Published
June 10, 2021
Journal
Frontiers in Psychology
Authors
Michael, P., Luke, D., Robinson, O.

Clinical Trials

3 trials
RecruitingPhase NA

Antidepressant Response of DMT Masked With Propofol (DMT4D)

This randomised, placebo-controlled, quadruple-masked trial (n=112) will investigate whether the antidepressant effects of DMT (2 mg/min over 20 minutes; total ~40 mg) in patients with MDD depend on the subjective psychedelic experience by comparing DMT vs placebo under propofol sedation or no sedation.

Started
April 1, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06927076
RecruitingPhase I

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants (LPD)

This randomised, placebo-controlled, triple-blind Phase I crossover trial (n=24) will compare the acute and subacute effects of LSD (150µg), psilocybin (30mg), and DMT (up to 2 mg/min intravenous infusion) in healthy adults, with all sessions standardised using ketanserin (20 mg IV) to end the psychedelic experience after three hours.

Started
April 1, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06899334
Active not recruitingPhase NA

Understanding Neuroplasticity Induced by TrYptamines (UNITy): the effects of dimethyltryptamine (DMT) on drinking

Randomised, double-blind, placebo-controlled 2×2 factorial mechanistic study (n=120) testing 25 mg IV DMT vs placebo combined with alcohol memory reactivation in non-treatment-seeking hazardous/harmful drinkers.

Started
October 30, 2020
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
ISRCTN13970288

Explore further

Search all DMT papers Search all Set & Setting trials Full DMT profile Full Set & Setting profile